

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4864394

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ELIANE H TREPAGNIER	02/08/2018
TARUN KUMAR KHURANA	03/06/2018

RECEIVING PARTY DATA

Name:	ILLUMINA, INC.
Street Address:	5200 ILLUMINA WAY
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92122

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15739587

CORRESPONDENCE DATA

Fax Number: (858)202-4545

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (858) 202-4500

Email: IlluminaDocket@Illumina.FoundationIP.com

Correspondent Name: MICHAEL REED

Address Line 1: ILLUMINA, INC.

Address Line 2: 5200 ILLUMINA WAY

Address Line 4: SAN DIEGO, CALIFORNIA 92122

ATTORNEY DOCKET NUMBER: IP-1371-US

NAME OF SUBMITTER: MICHELLE WALSH

SIGNATURE: /Michelle Walsh/

DATE SIGNED: 03/13/2018

Total Attachments: 8

source=IP-1371-US_Fully Executed Assignment#page1.tif

source=IP-1371-US_Fully Executed Assignment#page2.tif

source=IP-1371-US_Fully Executed Assignment#page3.tif

source=IP-1371-US_Fully Executed Assignment#page4.tif

PATENT

REEL: 045582 FRAME: 0523

source=IP-1371-US_Fully Executed Assignment#page5.tif
source=IP-1371-US_Fully Executed Assignment#page6.tif
source=IP-1371-US_Fully Executed Assignment#page7.tif
source=IP-1371-US_Fully Executed Assignment#page8.tif

ASSIGNMENT FROM INVENTORS

Docket No.: IP-1371-US

Page 1 of 4

Title: ORTHOGONAL DEBLOCKING OF NUCLEOTIDES

U.S. Application No.: 15/739,587

Filing Date: July 8, 2016

Inventor(s): Eliane H. TREPAGNIER, Tarun Kumar KHURANA

WHEREAS, above-identified inventors (collectively "the Assignors") have made certain new and useful inventions, discoveries, and improvements (the "Inventions"), for which the Assignors filed the applications listed above and now desire to convey all right, title, and interest in:

- * the Inventions,
- * the applications listed above, and any other applications for patent, design, utility model, certificate of invention, trademark, or trade dress, in any country or under any international or regional authority (e.g. WIPO/PCT, EPO, ARIPO, EAPO, OAPI), to the extent some or all of its subject matter is disclosed and entitled to the benefit of priority in the applications listed above, including provisional, continuation, divisional, continuation-in-part, reissues, and reexamination applications (collectively "the Applications"),
- * the benefit of earlier filing date and right to claim priority to the Inventions and Applications under applicable law and treaties, including the Paris Convention for the Protection of Industrial Property as revised and amended and 35 U.S.C. §§ 119, 120,
- * any rights accrued by the publication of the Applications, such as 35 U.S.C. § 154(d), Art. 67(1) EPC,
- * any Letters Patent or Certificates of Invention that may be issued or granted from the Applications, including reissued patents, reexamination certificates, renewals, and any rights resulting from an extension or adjustment of patent term, and
- * any rights arising from the Invention under laws and conventions protecting copyright, trademark, trade dress, or other industrial property,

(collectively, "the IP Rights"), and

WHEREAS, ILLUMINA, INC., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122, United States of America, is desirous of acquiring the entire right, title, and interest for itself, its successors, and its assigns (collectively "the Assignee") in the IP Rights by an instrument in writing, 35 U.S.C. § 261;

NOW, THEREFORE, to all whom it may concern, be it known that, for good and valuable consideration, the receipt and sufficiency of which we hereby acknowledge and hereby waive the right to any additional compensation concerning the IP Rights:

ASSIGNMENT FROM INVENTORS

Docket No.: IP-1371-US

Page 2 of 4

Title: ORTHOGONAL DEBLOCKING OF NUCLEOTIDES

U.S. Application No.: 15/739,587

Filing Date: July 8, 2016

Inventor(s): Eliane H. TREPAGNIER, Tarun Kumar KHURANA

We warrant and represent to the Assignee that we have the full right to convey our right, title, and interest in the IP Rights without encumbrance, and that we have not made any earlier assignment, license, grant, or mortgage to another, or made any agreement with another, that would affect our right, title, and interest in the IP Rights;

By this Assignment and by virtue of any earlier agreements to assign, we hereby assign, transfer, convey, and sell our entire right, title, and interest in the IP Rights to the Assignee, including any claims or causes of action for damages or other remedies arising out of any earlier violation of the IP Rights, for and to inure to the Assignee's full benefit of the IP Rights as fully as they would have been held by us if this Assignment had not been made;

We authorize the Assignee and its legal representatives to:

- (a) insert into this Assignment any supplemental information to make the identification more complete for any of the Applications or Letters Patent already listed above,
- (b) prosecute the Applications, file new applications for the inventions, and do all acts permitted by law to protect and enforce the IP Rights,
- (c) request that Letters Patent and Certificates of Invention be issued and granted to and in the name of the Assignee by the issuing or granting authority, such as the U.S. Commissioner for Patents, 37 C.F.R. § 3.81; and

We agree with the Assignee that we and our legal representatives, heirs, and executors will perform all acts deemed necessary or desirable by the Assignee to permit and assist it to secure the entire right, title, and interest in the IP Rights so that the Assignee may benefit from this Assignment, including:

- (a) communicating to the Assignee all facts known to us that relate to the history and extent of my individual contribution to the IP Rights, including the circumstances of the conception of the invention and its development and reduction to practice, and furnishing supporting documents or items in my control,
- (b) assisting in the preparation of the Applications and their prosecution by the Assignee, 37 C.F.R. § 3.71, and in the enforcement of the IP Rights, including making, executing, and delivering to the Assignee any other necessary documents, such as further application papers, declarations, affidavits, disclaimers, petitions, or assignments, and
- (c) assisting and cooperating in administrative and legal proceedings, including giving written and oral testimony,

ASSIGNMENT FROM INVENTORS

Docket No.: IP-1371-US

Page 3 of 4

Title: ORTHOGONAL DEBLOCKING OF NUCLEOTIDES

U.S. Application No.: 15/739,587

Filing Date: July 8, 2016

Inventor(s): Eliane H. TREPAGNIER, Tarun Kumar KHURANA

so that these will be performed without further consideration, except for reasonable actual expenses to be reimbursed by the Assignee.

We further agree with the Assignee that we will not perform any future act, execute any subsequent document, or make any subsequent agreement with another person or party that conflicts with this Assignment, that purports to transfer any right, title, or interest in the IP Rights that are the subject of this Assignment, unless agreed to in writing by the Assignee or that prevents the Assignee from receiving the full benefit of the bargain under this Assignment.

If any provision of this Assignment is held invalid or unenforceable, that provision shall be enforced to the maximum extent permissible in order to put into effect the intent of the Assignors and the Assignee, and the remainder of this Assignment shall not be affected, but continue in full force and effect.

This document shall be executable by each Assignor in parts, and the Assignment will be effective and recordable for each Assignor as of the date of that Assignor's signature.

Legal Name of Inventor: Eliane H. TREPAGNIER

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 8 day of February, 2016.

Signature: 

Legal Name of Inventor: Tarun Kumar KHURANA

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this _____ day of _____, 20_____.

Signature: 

PATENT

REEL: 045582 FRAME: 0527

ASSIGNMENT FROM INVENTORS

Docket No.: IP-1371-US

Page 4 of 4

Title: ORTHOGONAL DEBLOCKING OF NUCLEOTIDES

U.S. Application No.: 15/739,587

Filing Date: July 8, 2016

Inventor(s): Eliane H. TREPAGNIER, Tarun Kumar KHURANA

RECEIVED AND HEREBY ACCEPTED BY ILLUMINA, INC., a Delaware Corporation

Date:

March 12, 2018



Name: Roland Schwillinski

Title: Vice President, Global IP and Litigation

ASSIGNMENT FROM INVENTORS

Docket No.: IP-1371-US

Page 1 of 4

Title: ORTHOGONAL DEBLOCKING OF NUCLEOTIDES

U.S. Application No.: 15/739,587

Filing Date: July 8, 2016

Inventor(s): Ellane H. TREPAGNIER, Tarun Kumar KHURANA

WHEREAS, above-identified inventors (collectively "the Assignors") have made certain new and useful inventions, discoveries, and improvements (the "Inventions"), for which the Assignors filed the applications listed above and now desire to convey all right, title, and interest in:

- * the Inventions,
- * the applications listed above, and any other applications for patent, design, utility model, certificate of invention, trademark, or trade dress, in any country or under any international or regional authority (e.g. WIPO/PCT, EPO, ARIPO, EAPO, OAPI), to the extent some or all of its subject matter is disclosed and entitled to the benefit of priority in the applications listed above, including provisional, continuation, divisional, continuation-in-part, reissue, and reexamination applications (collectively "the Applications"),
- * the benefit of earlier filing date and right to claim priority to the Inventions and Applications under applicable law and treaties, including the Paris Convention for the Protection of Industrial Property as revised and amended and 35 U.S.C. §§ 119, 120,
- * any rights accrued by the publication of the Applications, such as 35 U.S.C. § 154(d), Art. 67(1) EPC,
- * any Letters Patent or Certificates of Invention that may be issued or granted from the Applications, including reissued patents, reexamination certificates, renewals, and any rights resulting from an extension or adjustment of patent term, and
- * any rights arising from the invention under laws and conventions protecting copyright, trademark, trade dress, or other industrial property,

(collectively, "the IP Rights"), and

WHEREAS, ILLUMINA, INC., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122, United States of America, is desirous of acquiring the entire right, title, and interest for itself, its successors, and its assigns (collectively "the Assignee") in the IP Rights by an instrument in writing, 35 U.S.C. § 261;

NOW, THEREFORE, to all whom it may concern, be it known that, for good and valuable consideration, the receipt and sufficiency of which we hereby acknowledge and hereby waive the right to any additional compensation concerning the IP Rights;

ASSIGNMENT FROM INVENTORS

Docket No.: IP-1371-US

Page 2 of 4

Title: ORTHOGONAL DEBLOCKING OF NUCLEOTIDES

U.S. Application No.: 15/739,587

Filing Date: July 8, 2016

Inventor(s): Eliane H. TREPAGNIER, Tarun Kumar KHURANA

We warrant and represent to the Assignee that we have the full right to convey our right, title, and interest in the IP Rights without encumbrance, and that we have not made any earlier assignment, license, grant, or mortgage to another, or made any agreement with another, that would affect our right, title, and interest in the IP Rights;

By this Assignment and by virtue of any earlier agreements to assign, we hereby assign, transfer, convey, and sell our entire right, title, and interest in the IP Rights to the Assignee, including any claims or causes of action for damages or other remedies arising out of any earlier violation of the IP Rights, for and to inure to the Assignee's full benefit of the IP Rights as fully as they would have been held by us if this Assignment had not been made;

We authorize the Assignee and its legal representatives to:

- (a) insert into this Assignment any supplemental information to make the identification more complete for any of the Applications or Letters Patent already listed above;
- (b) prosecute the Applications, file new applications for the inventions, and do all acts permitted by law to protect and enforce the IP Rights;
- (c) request that Letters Patent and Certificates of Invention be issued and granted to and in the name of the Assignee by the issuing or granting authority, such as the U.S. Commissioner for Patents, 37 C.F.R. § 3.81; and

We agree with the Assignee that we and our legal representatives, heirs, and executors will perform all acts deemed necessary or desirable by the Assignee to permit and assist it to secure the entire right, title, and interest in the IP Rights so that the Assignee may benefit from this Assignment, including:

- (a) communicating to the Assignee all facts known to us that relate to the history and extent of my individual contribution to the IP Rights, including the circumstances of the conception of the invention and its development and reduction to practice, and furnishing supporting documents or items in my control;
- (b) assisting in the preparation of the Applications and their prosecution by the Assignee, 37 C.F.R. § 3.71, and in the enforcement of the IP Rights, including making, executing, and delivering to the Assignee any other necessary documents, such as further application papers, declarations, affidavits, disclaimers, petitions, or assignments, and
- (c) assisting and cooperating in administrative and legal proceedings, including giving written and oral testimony,

ASSIGNMENT FROM INVENTORS

Docket No.: IP-1371-US

Page 3 of 4

Title: ORTHOGONAL DEBLOCKING OF NUCLEOTIDES

U.S. Application No.: 15/739,587

Filing Date: July 8, 2016

Inventor(s): Eliane H. TREPAGNIER, Tarun Kumar KHURANA

so that these will be performed without further consideration, except for reasonable actual expenses to be reimbursed by the Assignee.

We further agree with the Assignee that we will not perform any future act, execute any subsequent document, or make any subsequent agreement with another person or party that conflicts with this Assignment, that purports to transfer any right, title, or interest in the IP Rights that are the subject of this Assignment, unless agreed to in writing by the Assignee or that prevents the Assignee from receiving the full benefit of the bargain under this Assignment.

If any provision of this Assignment is held invalid or unenforceable, that provision shall be enforced to the maximum extent permissible in order to put into effect the intent of the Assignors and the Assignees, and the remainder of this Assignment shall not be affected, but continue in full force and effect.

This document shall be executable by each Assignor in parts, and the Assignment will be effective and recordable for each Assignor as of the date of that Assignor's signature.

Legal Name of Inventor: Eliane H. TREPAGNIER

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this _____ day of _____, 20_____.

Signature: _____

Legal Name of Inventor: Tarun Kumar KHURANA

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 6 day of March, 20118.

Signature: Tarun Kumar KHURANA

ASSIGNMENT FROM INVENTORS

Docket No.: IP-1371-US

Page 4 of 4

Title: ORTHOGONAL DEBLOCKING OF NUCLEOTIDES

U.S. Application No.: 15/739,587

Filing Date: July 8, 2016

Inventor(s): Eliane H. TREPAGNIER, Tarun Kumar KHURANA

RECEIVED AND HEREBY ACCEPTED BY ILLUMINA, INC., a Delaware Corporation

Date: 3/12/18



Name: Roland Schwillinski

Title: Vice President, Global IP and Litigation